A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma.

Dean A. Fennell,Amy King,Seid Mohammed,Amy Branson,Alastair Greystoke,Sam Moody,Margaret Hutka,Alan G Dawson,Liz Darlison,Molly Scotland,Vina Bhundia,Amrita Bajaj,Bruno Morgan,Adrian Nicholson,Cassandra Brookes,Aarti Gaba,Peter Wells-Jordan,Catherine Jane Richards,Anne L. Thomas

A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma.

2021

Dean A. Fennell
Amy King
Seid Mohammed
Amy Branson
Alastair Greystoke
Sam Moody
Margaret Hutka
Alan G Dawson
Liz Darlison
Molly Scotland
Vina Bhundia
Amrita Bajaj
Bruno Morgan
Adrian Nicholson
Cassandra Brookes
Aarti Gaba
Peter Wells-Jordan
Catherine Jane Richards
Anne L. Thomas

8558Background: Genetically stratified therapy for malignant mesothelioma (MM) is lacking. MMs frequently harbour loss of chromosome 9p21.3 locus (CDKN2A) associated with shorter survival. CDKN2A e...

Keywords:

Chromosome
Cancer research
in patient
Abemaciclib
Mesothelioma
Medicine
CDKN2A
Locus (genetics)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations